Home News

News

Update COVID-19: MabPlex is here for your ADC needs

As COVID-19 continues to have a significant impact on global supply chains and manufacturing, we want to share an update on what MabPlex is doing to keep our employees and customers safe as we...

MabPlex successfully hosted the Biopharmaceutical CMC Summit in Yantai

On November 8, 2019, Biopharmaceutical CMC Summit was successfully held in Yantai, China, which is also the fourth high-level biomedical summits hosted by MabPlex.

MabPlex Congratulates Encure Biopharma with FDA IND Clearance of YH001 for the Treatment of...

MabPlex International Ltd. confirms securing United States Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for Encure Biopharma Co., Ltd.’s (Beijing) YH001 Project. Following this successful FDA IND Clearance, MabPlex...

Introduction to MabPlex San Diego, Shanghai, and Yantai

MabPlex provides global CDMO services in the development and manufacturing of biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. We offer our partners contract services from DNA to finished drug product. At our US and Shanghia R&D sites and our manufacturing site in Yantai, China, MabPlex delivers truly integrated solution to our partners.

Development of Robust Processes for Large Scale ADC

IntroductionAntibody-drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. ADCs are composed of a monoclonal antibody (mAb) conjugated to a drug...

MabPlex Earns Frost & Sullivan Award

Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizes China-based MabPlex International, Ltd (MabPlex) with the 2019 Global Growth Excellence Leadership...

MabPlex Announces Appointment of Dr. Wei Chen as Chief Executive Officer

MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company's new Chief Executive Officer (CEO). Dr. Chen, a senior biopharmaceutical professional who has participated in the development of many novel therapeutic agents, will be responsible for MabPlex’s strategic planning and operations management, including the company's Chemistry, Manufacturing and Controls (CMC) operations.

MabPlex’s Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO ) offering services in the development and manufacturing of biopharmaceuticals, announced that an Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for its customer’s proprietary antibody drug.

MabPlex M2 Commercial Manufacturing Facility Opening Ceremony

MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO ) offering services in the development and manufacturing of biopharmaceuticals, announced the grand opening and ribbon-cutting ceremony of their new biopharmaceutical manufacturing facility in Yantai, Shandong (China). The ceremony took place on September 6, 2018.

MabPlex Announces the Opening of its San Diego, CA based Process Development Center of...

MabPlex, Inc., a subsidiary of MabPlex International, LTD, is excited to announce the establishment of our new state of the art Process Development Center of Excellence located in La Jolla, CA with...

Latest News